Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Rhea-AI Summary
Nektar Therapeutics (Nasdaq: NKTR) announced that company management will present at the Jefferies Global Healthcare Conference in London, held November 17-20, 2025.
The company will host a fireside chat on Thursday, November 20, 2025, webcast live at 11:00 a.m. GMT / 3:00 a.m. PT. The webcast is accessible via the company’s Investor Events webpage and a replay will be available for 30 days. Investors seeking one-on-one meetings should contact their Jefferies representative.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NKTR gained 5.32%, reflecting a notable positive market reaction. Argus tracked a peak move of +7.1% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $64M to the company's valuation, bringing the market cap to $1.27B at that time.
Data tracked by StockTitan Argus on the day of publication.
- Jefferies Global Healthcare Conference in
London on Thursday, November 20, 2025 – webcast to be available at 11:00 a.m. Greenwich Mean Time / 3:00 a.m. Pacific Time – link here
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your Jefferies representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered in
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
Jonathan Pappas
LifeSci Communications
857-205-4403
jpappas@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference-in-london-302600127.html
SOURCE Nektar Therapeutics
FAQ
When will Nektar Therapeutics (NKTR) present at the Jefferies Global Healthcare Conference in London?
What time is the NKTR webcast for the Jefferies conference and how can I watch it?
Will there be a replay of Nektar's (NKTR) Jefferies presentation and for how long?
How can investors request a one-on-one meeting with Nektar management at the Jefferies London conference?
Where on Nektar's website will the Jefferies conference webcast for NKTR be posted?
Is the NKTR Jefferies conference webcast available to the public or only to investors?
